About Glutamine amidotransferase-like class 1 domain-containing protein 1
Glutamine amidotransferase-like class 1 domain-containing protein 1 (GATD1) is a protein
from Homo sapiens identified by UniProt accession
Q8NB37, 220 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Glutamine amidotransferase-like class 1 domain-containing protein 1 |
|---|
| UniProt accession | Q8NB37 |
|---|
| Gene | GATD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 220 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (12)
Diseases linked to this target (Open Targets).
- pulse pressure measurement · score 0.09
- low density lipoprotein cholesterol measurement · score 0.06
- corneal endothelial cell measurement · score 0.05
- mean reticulocyte volume · score 0.05
- intraocular pressure measurement · score 0.04
- BMI-adjusted waist circumference · score 0.03
- COVID-19 · score 0.01
- transaldolase deficiency · score 0.01
- glioblastoma multiforme · score 0.00
- squamous cell carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NB37-F1 | alphafold | PREDICTED | 94.89 | — |
Amino-acid sequence (220 residues)
MASERLPNRP ACLLVASGAA EGVSAQSFLH CFTMASTAFN LQVATPGGKA MEFVDVTESN ARWVQDFRLK AYASPAKLES IDGARYHALL IPSCPGALTD LASSGSLARI LQHFHSESKP ICAVGHGVAA LCCATNEDRS WVFDSYSLTG PSVCELVRAP GFARLPLVVE DFVKDSGACF SASEPDAVHV VLDRHLVTGQ NASSTVPAVQ NLLFLCGSRK
Explore Glutamine amidotransferase-like class 1 domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets